BMC Cancer (Dec 2022)

IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation

  • Taigo Kato,
  • Nobuaki Matsubara,
  • Masaki Shiota,
  • Masatoshi Eto,
  • Takahiro Osawa,
  • Takashige Abe,
  • Nobuo Shinohara,
  • Yota Yasumizu,
  • Nobuyuki Tanaka,
  • Mototsugu Oya,
  • Koshiro Nishimoto,
  • Takuji Hayashi,
  • Masashi Nakayama,
  • Takahiro Kojima,
  • Kenjiro Namikawa,
  • Takao Fujisawa,
  • Susumu Okano,
  • Eisuke Hida,
  • Yoshiaki Nakamura,
  • Hideaki Bando,
  • Takayuki Yoshino,
  • Norio Nonomura

DOI
https://doi.org/10.1186/s12885-022-10398-6
Journal volume & issue
Vol. 22, no. 1
pp. 1 – 6

Abstract

Read online

Abstract Background Previous clinical trials have demonstrated the potential efficacy of poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) in patients with cancer involving homologous recombination repair (HRR) gene-mutation. Moreover, HRR gene-mutated cancers are effectively treated with immune checkpoint inhibitors (ICIs) with the increase in tumor mutation burden. We have proposed to conduct a multicenter, single-arm phase II trial (IMAGENE trial) for evaluating the efficacy and safety of niraparib (PARPi) plus programmed cell death-1 inhibitor combination therapy in patients with HRR gene-mutated cancers who are refractory to ICIs therapy using a next generation sequencing-based circulating tumor DNA (ctDNA) and tumor tissue analysis. Methods Key eligibility criteria for this trial includes HRR gene-mutated tumor determined by any cancer gene tests; progression after previous ICI treatment; and Eastern Cooperative Oncology Group Performance Status ≤ 1. The primary endpoint is the confirmed objective response rate (ORR) in all patients. The secondary endpoints include the confirmed ORR in patients with HRR gene-mutation of ctDNA using the Caris Assure (CARIS, USA). The target sample size of the IMAGENE trial is 57 patients. Biomarker analyses will be performed in parallel using the Caris Assure, proteome analysis, and T cell repertoire analysis to reveal tumor immunosurveillance in peripheral blood. Expected outcome Our trial aims to confirm the clinical benefit of PARPi plus ICI combination therapy in ICI-resistant patients. Furthermore, through translational research, our trial will shed light on which patients would benefit from the targeted combination therapy for patients with HRR gene-mutated tumor even after the failure of ICIs. Trial registration The IMAGENE trial: jRCT, Clinical trial no.: jRCT2051210120, Registered date: November 9, 2021.

Keywords